PHARMENA SA engages in developing and marketing products based on a patented, physiological, and natural active substance 1-MNA. It focuses on clinical research on innovative anti-atherosclerotic medicinal product, production of innovative dermatological products, and introduction of innovative dietary supplement used for special nutritional needs in the prevention of atherosclerosis. It distributes its products under the Menavitim, Dermena, Allerco, and Thermi brands. The company was founded by Jerzy Gebicki on November 12, 2002 and is headquartered in Lodz, Poland.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company